{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:46:52Z","timestamp":1789519612494,"version":"build-2803163510"},"reference-count":195,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jaut.2022.102887","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T21:13:02Z","timestamp":1661375582000},"page":"102887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"special_numbering":"C","title":["Systemic lupus erythematosus-complicating immune thrombocytopenia: From pathogenesis to treatment"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6269-0172","authenticated-orcid":false,"given":"Ying","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiliang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8775-1699","authenticated-orcid":false,"given":"Xuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2022.102887_bib1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2016.07.001","article-title":"The diagnosis and management of the haematologic manifestations of lupus","volume":"74","author":"Velo-Garcia","year":"2016","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2022.102887_bib2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10067-013-2383-3","article-title":"Death causes and pathogens analysis of systemic lupus erythematosus during the past 26 years","volume":"33","author":"Fei","year":"2014","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2022.102887_bib3","doi-asserted-by":"crossref","first-page":"601","DOI":"10.55563\/clinexprheumatol\/bz64na","article-title":"Prevalence and outcome of thrombocytopenia in systemic lupus erythematous: single-centre cohort analysis","volume":"39","author":"Costa","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2022.102887_bib4","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/annrheumdis-2020-217356","article-title":"Population-based studies in systemic lupus erythematosus: immune thrombocytopenic purpura or 'blood-dominant' lupus?","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2022.102887_bib5","series-title":"Immune Thrombocytopenia with Clinical Significance in Systemic Lupus Erythematosus: A Retrospective Cohort Study of 90 Patients, Rheumatology","author":"Roussotte","year":"2021"},{"key":"10.1016\/j.jaut.2022.102887_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12016-020-08817-2","article-title":"Management of severe refractory systemic lupus erythematosus: real-World experience and literature review","volume":"60","author":"Yang","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jaut.2022.102887_bib7","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2022.102887_bib8","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1007\/s10067-018-4312-y","article-title":"Severe thrombocytopenia in connective tissue diseases: a single-center review of 131 cases","volume":"37","author":"Zhang","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2022.102887_bib9","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.3899\/jrheum.150829","article-title":"Bone marrow megakaryocytes may predict therapeutic response of severe thrombocytopenia in patients with systemic lupus erythematosus","volume":"43","author":"Zhao","year":"2016","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2022.102887_bib10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrrheum.2018.38","article-title":"The non-haemostatic role of platelets in systemic lupus erythematosus","volume":"14","author":"Linge","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2022.102887_bib11","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1007\/s10067-019-04483-8","article-title":"The efficacy and safety of antithrombotic therapy in patients with positive antiphospholipid antibodies receiving invasive procedures: experience from a single tertiary center","volume":"38","author":"Chen","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2022.102887_bib12","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/annrheumdis-2020-217013","article-title":"Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a population-based cohort study","volume":"79","author":"Zhu","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2022.102887_bib13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12865-014-0061-0","article-title":"In silico analysis of autoimmune diseases and genetic relationships to vaccination against infectious diseases","volume":"15","author":"Mcgarvey","year":"2014","journal-title":"BMC Immunol."},{"key":"10.1016\/j.jaut.2022.102887_bib14","doi-asserted-by":"crossref","first-page":"189r","DOI":"10.1126\/scitranslmed.3006277","article-title":"Plasmacytoid dendritic cells, interferon signaling, and FcgammaR contribute to pathogenesis and therapeutic response in childhood immune thrombocytopenia","volume":"5","author":"Sehgal","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jaut.2022.102887_bib15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/1087057116664029","article-title":"Identification and validation of gene expression pattern and signature in patients with immune thrombocytopenia","volume":"22","author":"Ye","year":"2017","journal-title":"SLAS Discov"},{"key":"10.1016\/j.jaut.2022.102887_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9030712","article-title":"New horizons in the genetic etiology of systemic lupus erythematosus and Lupus-Like disease: monogenic lupus and beyond","volume":"9","author":"Demirkaya","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jaut.2022.102887_bib17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41586-022-04642-z","article-title":"TLR7 gain-of-function genetic variation causes human lupus","volume":"605","author":"Brown","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2022.102887_bib18","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/aje\/kwz074","article-title":"Association of scrub typhus with the risk of autoimmune diseases: a Population-Based cohort study","volume":"188","author":"Chu","year":"2019","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.jaut.2022.102887_bib19","first-page":"1","article-title":"Response to: \u2018Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: population-based cohort study\u2019 by Goulielmos and Zervou","volume":"0","author":"Zhu","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2022.102887_bib20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1179\/1607845413Y.0000000084","article-title":"The role of Epstein-Barr virus (EBV) and cytomegalovirus (CMV) in immune thrombocytopenia","volume":"18","author":"Wu","year":"2013","journal-title":"Hematology"},{"key":"10.1016\/j.jaut.2022.102887_bib21","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical features of Vaccine-Induced immune thrombocytopenia and thrombosis","volume":"385","author":"Pavord","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2022.102887_bib22","article-title":"Helicobacter pylori and autoimmune diseases: involving multiple systems","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2022.102887_bib23","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10067-019-04805-w","article-title":"Helicobacter pylori infection and gastroduodenal lesions in patients with systemic lupus erythematosus","volume":"39","author":"Mendoza-Pinto","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2022.102887_bib24","doi-asserted-by":"crossref","first-page":"12818","DOI":"10.3748\/wjg.v20.i36.12818","article-title":"Hematologic manifestations of Helicobacter pylori infection","volume":"20","author":"Campuzano-Maya","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jaut.2022.102887_bib25","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1080\/09537104.2021.1945570","article-title":"Helicobacter pylori protein that binds to and activates platelet specifically reacts with sera of H. Pylori-associated chronic immune thrombocytopenia","volume":"32","author":"Takeuchi","year":"2021","journal-title":"Platelets"},{"key":"10.1016\/j.jaut.2022.102887_bib26","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3748\/wjg.v20.i3.714","article-title":"Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms","volume":"20","author":"Kuwana","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jaut.2022.102887_bib27","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/ajh.25829","article-title":"Hematological findings and complications of COVID-19","volume":"95","author":"Terpos","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jaut.2022.102887_bib28","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00296-021-04794-7","article-title":"Can the SARS-CoV-2 infection trigger systemic lupus erythematosus? A case-based review","volume":"41","author":"Gracia-Ramos","year":"2021","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.jaut.2022.102887_bib29","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1136\/annrheumdis-2020-218157","article-title":"Exacerbation of immune thrombocytopenia triggered by COVID-19 in patients with systemic lupus erythematosus","volume":"80","author":"Kondo","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2022.102887_bib30","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1007\/s10067-021-05691-x","article-title":"COVID-19 and the clinical course of rheumatic manifestations","volume":"40","author":"Ahmed","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2022.102887_bib31","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/cmi.2017.123","article-title":"TLR7, a third signal for the robust generation of spontaneous germinal center B cells in systemic lupus erythematosus, Cell","volume":"15","author":"Fan","year":"2018","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jaut.2022.102887_bib32","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3389\/fimmu.2018.00880","article-title":"Emerging concepts in immune thrombocytopenia","volume":"9","author":"Swinkels","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2022.102887_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22179615","article-title":"Megakaryopoiesis and platelet biology: roles of transcription factors and emerging clinical implications","volume":"22","author":"Noh","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jaut.2022.102887_bib34","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1080\/09537104.2021.1925102","article-title":"The thrombopoietin receptor: revisiting the master regulator of platelet production","volume":"32","author":"Hitchcock","year":"2021","journal-title":"Platelets"},{"key":"10.1016\/j.jaut.2022.102887_bib35","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/10408363.2016.1200008","article-title":"Platelets are versatile cells: new discoveries in hemostasis, thrombosis, immune responses, tumor metastasis and beyond","volume":"53","author":"Xu","year":"2016","journal-title":"Crit. Rev. Clin. Lab Sci."},{"key":"10.1016\/j.jaut.2022.102887_bib36","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3109\/09537104.2016.1171304","article-title":"Glycans and the platelet life cycle","volume":"27","author":"Li","year":"2016","journal-title":"Platelets"},{"key":"10.1016\/j.jaut.2022.102887_bib37","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/rheumatology\/kel010","article-title":"Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus","volume":"45","author":"Kuwana","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2022.102887_bib38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2249.2006.03122.x","article-title":"Suspects in the tale of lupus-associated thrombocytopenia","volume":"145","author":"Ziakas","year":"2006","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jaut.2022.102887_bib39","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/rheumatology\/kei118","article-title":"Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism","volume":"45","author":"Nakamura","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2022.102887_bib40","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.4049\/jimmunol.162.7.4311","article-title":"The role of the human Fc receptor Fc gamma RIIA in the immune clearance of platelets: a transgenic mouse model","volume":"162","author":"Mckenzie","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2022.102887_bib41","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1600-0609.2011.01718.x","article-title":"Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP)","volume":"88","author":"Najaoui","year":"2012","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.jaut.2022.102887_bib42","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/rth2.12388","article-title":"Serum complement levels in immune thrombocytopenia: characterization and relation to clinical features","volume":"4","author":"Cheloff","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jaut.2022.102887_bib43","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/bjh.17872","article-title":"Novel therapies for immune thrombocytopenia","volume":"196","author":"Kuter","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jaut.2022.102887_bib44","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3389\/fimmu.2019.00885","article-title":"Opposite profiles of complement in antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) among patients with antiphospholipid antibodies (aPL)","volume":"10","author":"Savelli","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2022.102887_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160563","article-title":"Platelet apoptosis in adult immune thrombocytopenia: insights into the mechanism of damage triggered by Auto-Antibodies","volume":"11","author":"Goette","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2022.102887_bib46","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MOH.0000000000000612","article-title":"An update on the pathophysiology of immune thrombocytopenia","volume":"27","author":"Semple","year":"2020","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.jaut.2022.102887_bib47","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s11427-015-4953-x","article-title":"B cells biology in systemic lupus erythematosus-from bench to bedside","volume":"58","author":"Zhao","year":"2015","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.jaut.2022.102887_bib48","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1538-7836.2008.03161.x","article-title":"Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura","volume":"7","author":"Kuwana","year":"2009","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.jaut.2022.102887_bib49","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1172\/JCI65689","article-title":"B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells","volume":"123","author":"Mahevas","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2022.102887_bib50","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3389\/fmed.2020.00303","article-title":"Belimumab and rituximab in systemic lupus erythematosus: a tale of two b Cell-Targeting agents","volume":"7","author":"Wise","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.jaut.2022.102887_bib51","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10875-005-4091-5","article-title":"Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren's syndrome","volume":"25","author":"Jonsson","year":"2005","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.jaut.2022.102887_bib52","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.clim.2017.12.010","article-title":"Effect of glucocorticoid treatment on BAFF and APRIL expression in patients with immune thrombocytopenia (ITP)","volume":"188","author":"Kamhieh-Milz","year":"2018","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jaut.2022.102887_bib53","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","article-title":"The BAFF\/APRIL system in SLE pathogenesis","volume":"10","author":"Vincent","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2022.102887_bib54","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1182\/bloodadvances.2020003860","article-title":"Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia","volume":"5","author":"Yu","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaut.2022.102887_bib55","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1177\/0961203310375268","article-title":"Expressions of BAFF\/BAFF receptors and their correlation with disease activity in Chinese SLE patients","volume":"19","author":"Zhao","year":"2010","journal-title":"Lupus"},{"issue":"Suppl 1","key":"10.1016\/j.jaut.2022.102887_bib56","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1053\/j.seminhematol.2013.03.014","article-title":"B-cell depletion in immune thrombocytopenia","volume":"50","author":"Godeau","year":"2013","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.jaut.2022.102887_bib57","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.3324\/haematol.2020.259481","article-title":"Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial","volume":"106","author":"Mahevas","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jaut.2022.102887_bib58","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-Year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2022.102887_bib59","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.jaut.2022.102887_bib60","first-page":"1056","article-title":"Efficacy of belimumab for the long-term maintenance therapy of thrombocytopenia in systemic lupus erythematosus","volume":"35","author":"De Marchi","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2022.102887_bib61","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ejh.13705","article-title":"T cell-mediated autoimmunity in immune thrombocytopenia","volume":"108","author":"Vrbensky","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.jaut.2022.102887_bib62","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1111\/bjh.16334","article-title":"Increased cytotoxic potential of CD8(+) T cells in immune thrombocytopenia","volume":"188","author":"Vrbensky","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jaut.2022.102887_bib63","first-page":"914","article-title":"Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura","volume":"90","author":"Wang","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.jaut.2022.102887_bib64","doi-asserted-by":"crossref","first-page":"916","DOI":"10.4049\/jimmunol.1200580","article-title":"Platelets present antigen in the context of MHC class I","volume":"189","author":"Chapman","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2022.102887_bib65","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1160\/TH05-04-0270","article-title":"CD40-CD40L interactions in platelet activation","volume":"93","author":"Davi","year":"2005","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.jaut.2022.102887_bib66","article-title":"CD8(+) T cells induce platelet clearance in the liver via platelet desialylation in immune thrombocytopenia","volume":"6","author":"Qiu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jaut.2022.102887_bib67","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1111\/bjh.16334","article-title":"Increased cytotoxic potential of CD8(+) T cells in immune thrombocytopenia","volume":"188","author":"Vrbensky","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jaut.2022.102887_bib68","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1182\/blood-2013-03-491415","article-title":"Preferential splenic CD8(+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia","volume":"122","author":"Audia","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2022.102887_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.630693","article-title":"Low-Dose decitabine inhibits cytotoxic t Lymphocytes-Mediated platelet destruction via modulating PD-1 methylation in immune thrombocytopenia","volume":"12","author":"Han","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2022.102887_bib70","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1182\/blood-2014-03-563445","article-title":"Splenic TFH expansion participates in B-cell differentiation and antiplatelet-antibody production during immune thrombocytopenia","volume":"124","author":"Audia","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2022.102887_bib71","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1177\/0961203310367583","article-title":"Regulatory T-cells in systemic lupus erythematosus-associated thrombocytopenia: a comparison with idiopathic thrombocytopenic purpura","volume":"24","author":"Park","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2022.102887_bib72","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.thromres.2022.02.021","article-title":"HMGB1 is increased in patients with immune thrombocytopenia and negatively associates with Tregs","volume":"213","author":"Zhang","year":"2022","journal-title":"Thromb. Res."},{"key":"10.1016\/j.jaut.2022.102887_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12691","article-title":"Sialic acid and platelet count regulation: implications in immune thrombocytopenia","volume":"6","author":"Lee-Sundlov","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jaut.2022.102887_bib74","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1080\/09537104.2021.1988547","article-title":"Pathogenic mechanisms contributing to thrombocytopenia in patients with systemic lupus erythematosus","volume":"33","author":"Baroni","year":"2022","journal-title":"Platelets"},{"key":"10.1016\/j.jaut.2022.102887_bib75","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2021.279751","article-title":"Antiplatelet antibody predicts platelet desialylation and apoptosis in immune thrombocytopenia","author":"Zheng","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.jaut.2022.102887_bib76","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(21)00030-2","article-title":"Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial","volume":"8","author":"Sun","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jaut.2022.102887_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/cells10123386","article-title":"Platelet activation mechanisms and consequences of immune thrombocytopenia","volume":"10","author":"Sun","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jaut.2022.102887_bib78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086943","article-title":"Detection of circulating B cells producing anti-GPIb autoantibodies in patients with immune thrombocytopenia","volume":"9","author":"Kuwana","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2022.102887_bib79","doi-asserted-by":"crossref","first-page":"E1550","DOI":"10.1073\/pnas.1720553115","article-title":"Platelets release pathogenic serotonin and return to circulation after immune complex-mediated sequestration","volume":"115","author":"Cloutier","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jaut.2022.102887_bib80","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav5928","article-title":"Platelets release mitochondrial antigens in systemic lupus erythematosus","volume":"13","author":"Melki","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jaut.2022.102887_bib81","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1182\/bloodadvances.2020003860","article-title":"Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia","volume":"5","author":"Yu","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaut.2022.102887_bib82","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1136\/ard.2007.087478","article-title":"Anti-thrombopoietin antibodies suppress megakaryocytic colony formation in vitro in patients with systemic lupus erythaematosus","volume":"67","author":"Ziakas","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2022.102887_bib83","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1002\/art.10420","article-title":"Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia","volume":"46","author":"Kuwana","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2022.102887_bib84","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/0961203307086032","article-title":"Successful treatment of amegakaryocytic thrombocytopenia with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus","volume":"17","author":"Fukushima","year":"2008","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2022.102887_bib85","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12506","article-title":"GPIbalpha is the driving force of hepatic thrombopoietin generation","volume":"5","author":"Karakas","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jaut.2022.102887_bib86","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00277-016-2641-y","article-title":"Abnormalities of the bone marrow immune microenvironment in patients with immune thrombocytopenia","volume":"95","author":"Song","year":"2016","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.jaut.2022.102887_bib87","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/bloodadvances.2020001846","article-title":"Platelet autoantibodies in the bone marrow of patients with immune thrombocytopenia","volume":"4","author":"Shrestha","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaut.2022.102887_bib88","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/imr.12011","article-title":"The establishment of the plasma cell survival niche in the bone marrow","volume":"251","author":"Chu","year":"2013","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jaut.2022.102887_bib89","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.7150\/ijbs.33779","article-title":"Disrupted balance of CD4(+) T-cell subsets in bone marrow of patients with primary immune thrombocytopenia","volume":"15","author":"Wang","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.jaut.2022.102887_bib90","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2141.2007.06737.x","article-title":"CD8+ T cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura","volume":"139","author":"Li","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jaut.2022.102887_bib91","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-021-00627-y","article-title":"M2 macrophages, but not M1 macrophages, support megakaryopoiesis by upregulating PI3K-AKT pathway activity","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.jaut.2022.102887_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106096","article-title":"Discovery of a novel megakaryopoiesis enhancer, ingenol, promoting thrombopoiesis through PI3K-Akt signaling independent of thrombopoietin","volume":"177","author":"Wang","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jaut.2022.102887_bib93","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1136\/lupus-2014-000078","article-title":"Haematological manifestations of lupus","volume":"2","author":"Fayyaz","year":"2015","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.jaut.2022.102887_bib94","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaut.2022.102887_bib95","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/BOR.0000000000000599","article-title":"Treatment of primary and secondary immune thrombocytopenia","volume":"31","author":"Kado","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jaut.2022.102887_bib96","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1007\/s10067-020-05152-x","article-title":"Rituximab or cyclosporin in refractory immune thrombocytopenia secondary to connective tissue diseases: a real-world observational retrospective study","volume":"39","author":"Sun","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2022.102887_bib97","first-page":"829","article-title":"Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count","volume":"90","author":"Khellaf","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.jaut.2022.102887_bib98","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2022.102887_bib99","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1177\/09612033211034233","article-title":"Immature platelet levels correlate with disease activity and predict treatment response of thrombocytopenia in lupus patients","volume":"30","author":"Hanata","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2022.102887_bib100","first-page":"1","article-title":"Association between megakaryocyte abnormalities on bone marrow smear and response to thrombopoietin receptor agonists in adult patients with primary immune thrombocytopenia","author":"Walter","year":"2022","journal-title":"Platelets"},{"key":"10.1016\/j.jaut.2022.102887_bib101","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaut.2022.102887_bib102","article-title":"A practical perspective of the hematologic manifestations of systemic lupus erythematosus","volume":"14","author":"Santacruz","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.jaut.2022.102887_bib103","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/vox.12467","article-title":"New aspects on the efficacy of high-dose intravenous immunoglobulins in patients with autoimmune thrombocytopenia","volume":"112","author":"Mayer","year":"2017","journal-title":"Vox Sang."},{"key":"10.1016\/j.jaut.2022.102887_bib104","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/jth.12524","article-title":"Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study","volume":"12","author":"Peng","year":"2014","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.jaut.2022.102887_bib105","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1055\/s-0039-1700512","article-title":"Immune thrombocytopenia in adults: modern approaches to diagnosis and treatment","volume":"46","author":"Al-Samkari","year":"2020","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.jaut.2022.102887_bib106","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ajh.23609","article-title":"Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies","volume":"89","author":"Khellaf","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jaut.2022.102887_bib107","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3346\/jkms.2013.28.3.472","article-title":"Two cases of refractory thrombocytopenia in systemic lupus erythematosus that responded to intravenous low-dose cyclophosphamide","volume":"28","author":"Park","year":"2013","journal-title":"J. Kor. Med. Sci."},{"key":"10.1016\/j.jaut.2022.102887_bib108","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2100596","article-title":"Mycophenolate mofetil for First-Line treatment of immune thrombocytopenia","volume":"385","author":"Bradbury","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2022.102887_bib109","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/BOR.0000000000000523","article-title":"Autoimmune haemolytic anaemia and autoimmune thrombocytopenia in childhood-onset systemic lupus erythematosus: updates on pathogenesis and treatment","volume":"30","author":"Neely","year":"2018","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jaut.2022.102887_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106895","article-title":"Sirolimus versus cyclosporine for the treatment of pediatric chronic immune thrombocytopenia: a randomized blinded trial","volume":"88","author":"Mousavi-Hasanzadeh","year":"2020","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.jaut.2022.102887_bib111","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/548085","article-title":"Effects of rapamycin combined with low dose prednisone in patients with chronic immune thrombocytopenia","author":"Li","year":"2013","journal-title":"Clin. Dev. Immunol. 2013"},{"key":"10.1016\/j.jaut.2022.102887_bib112","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0140-6736(18)30485-9","article-title":"Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1\/2 trial","volume":"391","author":"Lai","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2022.102887_bib113","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1093\/rheumatology\/keaa645","article-title":"Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial","volume":"60","author":"Wu","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2022.102887_bib114","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/S2352-3026(15)00003-4","article-title":"Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"2","author":"Chugh","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jaut.2022.102887_bib115","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2014-06-582346","article-title":"Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients","volume":"124","author":"Khellaf","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2022.102887_bib116","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ajh.24999","article-title":"Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: a multicenter retrospective cohort study of 71 adults","volume":"93","author":"Serris","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jaut.2022.102887_bib117","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/RHU.0000000000000273","article-title":"Efficacy and safety of rituximab in systemic lupus erythematosus and sjogren syndrome patients with refractory thrombocytopenia: a retrospective study of 21 cases","volume":"21","author":"Jiang","year":"2015","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2022.102887_bib118","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9992086","article-title":"The efficacy and safety of different dosages of rituximab for adults with immune thrombocytopenia: a systematic review and Meta-Analysis","volume":"2021","author":"Dong","year":"2021","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.jaut.2022.102887_bib119","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3324\/haematol.2019.218883","article-title":"Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?","volume":"104","author":"Lucchini","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jaut.2022.102887_bib120","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update omicronn the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2022.102887_bib121","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1093\/rheumatology\/ker176","article-title":"Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus--a prospective pilot study","volume":"50","author":"Chen","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2022.102887_bib122","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaut.2015.05.006","article-title":"Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab","volume":"62","author":"Mahevas","year":"2015","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2022.102887_bib123","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3389\/fimmu.2013.00494","article-title":"Long-lived plasma cells in autoimmunity: lessons from B-cell depleting therapy","volume":"4","author":"Mahevas","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2022.102887_bib124","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s12016-020-08820-7","article-title":"B cell aberrance in lupus: the ringleader and the solution","volume":"62","author":"Nie","year":"2022","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jaut.2022.102887_bib125","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3389\/fimmu.2019.01540","article-title":"The neonatal fc receptor (FcRn): a misnomer?","volume":"10","author":"Pyzik","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2022.102887_bib126","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/cpt.1276","article-title":"M281, an Anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a First-in-Human study","volume":"105","author":"Ling","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jaut.2022.102887_bib127","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/bloodadvances.2020002003","article-title":"Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia","volume":"4","author":"Robak","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaut.2022.102887_bib128","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jaut.2022.102887_bib129","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: a crucial player in diverse biological functions","volume":"10","author":"Mocsai","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jaut.2022.102887_bib130","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood-2018-11-852491","article-title":"Fostamatinib for the treatment of chronic immune thrombocytopenia","volume":"133","author":"Connell","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2022.102887_bib131","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jaut.2022.102887_bib132","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jaut.2022.102887_bib133","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJMoa2110297","article-title":"Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia","volume":"386","author":"Kuter","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2022.102887_bib134","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13075-020-02372-z","article-title":"Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients","volume":"23","author":"Marken","year":"2021","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2022.102887_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121162","article-title":"An optimally designed anti-human CD40 antibody with potent B cell suppression for the treatment of autoimmune diseases","volume":"609","author":"Wu","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jaut.2022.102887_bib136","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2141.2008.07039.x","article-title":"The effect of anti-CD40 ligand in immune thrombocytopenic purpura","volume":"141","author":"Patel","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jaut.2022.102887_bib137","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.molmed.2022.04.010","article-title":"Therapeutic potential of interleukin-2 in autoimmune diseases","volume":"28","author":"Yuan","year":"2022","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jaut.2022.102887_bib138","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12185-013-1382-0","article-title":"The biology of thrombopoietin and thrombopoietin receptor agonists","volume":"98","author":"Kuter","year":"2013","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.jaut.2022.102887_bib139","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/bjh.16958","article-title":"Fine-tuning the treatment toolbox of immune thrombocytopenia: fostamatinib as a second-line therapy","volume":"190","author":"Kapur","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jaut.2022.102887_bib140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00277-021-04637-2","article-title":"Eltrombopag treatment of patients with secondary immune thrombocytopenia: retrospective EHR analysis","volume":"101","author":"Patwardhan","year":"2022","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.jaut.2022.102887_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103820","article-title":"Recent advances in the mechanisms and treatment of immune thrombocytopenia","volume":"76","author":"Provan","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jaut.2022.102887_bib142","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40265-021-01553-7","article-title":"Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists","volume":"81","author":"Gilreath","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jaut.2022.102887_bib143","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.3899\/jrheum.140080","article-title":"Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus","volume":"41","author":"Magnano","year":"2014","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2022.102887_bib144","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/RHU.0000000000001083","article-title":"Eltrombopag: efficacy and safety in steroid refractory Lupus-Associated immune thrombocytopenia","volume":"26","author":"Shobha","year":"2020","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2022.102887_bib145","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1177\/0961203314559632","article-title":"Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus","volume":"24","author":"Maroun","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2022.102887_bib146","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1038\/s41598-021-84493-2","article-title":"Eltrombopag for the treatment of refractory thrombocytopenia associated with connective tissue disease","volume":"11","author":"Wang","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jaut.2022.102887_bib147","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1177\/0961203318770023","article-title":"Safety and efficacy of thrombopoeitin mimetics for refractory immune thrombocytopenia purpura in patients with systemic lupus erythematosus or antiphospholipid syndrome: a case series","volume":"27","author":"Lusa","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2022.102887_bib148","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1177\/09612033211065140","article-title":"Catastrophic anti-phospholipid syndrome with Libman-Sacks endocarditis following eltrombopag therapy for immune thrombocytopenic purpura: a case report","volume":"30","author":"Dichtwald","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2022.102887_bib149","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1016\/S2352-3026(17)30167-9","article-title":"Is oral all-trans retinoic acid plus danazol a refinement of second-line therapy for primary immune thrombocytopenia in adults?","volume":"4","author":"Panzer","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jaut.2022.102887_bib150","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.1016\/S2352-3026(17)30170-9","article-title":"Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial","volume":"4","author":"Feng","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jaut.2022.102887_bib151","doi-asserted-by":"crossref","first-page":"723","DOI":"10.7326\/0003-4819-111-9-723","article-title":"Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women","volume":"111","author":"Ahn","year":"1989","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jaut.2022.102887_bib152","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1080\/09537104.2021.1988547","article-title":"Pathogenic mechanisms contributing to thrombocytopenia in patients with systemic lupus erythematosus","volume":"33","author":"Baroni","year":"2022","journal-title":"Platelets"},{"key":"10.1016\/j.jaut.2022.102887_bib153","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1080\/09537104.2018.1513476","article-title":"Multirefractory primary immune thrombocytopenia; Targeting the decreased sialic acid content","volume":"30","author":"Revilla","year":"2019","journal-title":"Platelets"},{"key":"10.1016\/j.jaut.2022.102887_bib154","doi-asserted-by":"crossref","first-page":"e688","DOI":"10.1016\/S2352-3026(21)00240-4","article-title":"All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"8","author":"Huang","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jaut.2022.102887_bib155","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3324\/haematol.2018.204446","article-title":"All-trans retinoic acid protects mesenchymal stem cells from immune thrombocytopenia by regulating the complement-interleukin-1beta loop","volume":"104","author":"Zhu","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jaut.2022.102887_bib156","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2008-07-167155","article-title":"Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review","volume":"113","author":"Stasi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2022.102887_bib157","doi-asserted-by":"crossref","first-page":"9370","DOI":"10.1038\/s41598-020-66460-5","article-title":"Helicobacter pylori eradication affects platelet count recovery in immune thrombocytopenia","volume":"10","author":"Lee","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jaut.2022.102887_bib158","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/0961203320923393","article-title":"Effect of early eradication therapy on systemic lupus erythematosus risk in patients with Helicobacter pylori infection: a nationwide population-based cohort study","volume":"29","author":"Wu","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2022.102887_bib159","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cyto.2015.08.001","article-title":"Recombinant human interleukin-11 (IL-11) is a protective factor in severe sepsis with thrombocytopenia: a case-control study","volume":"76","author":"Wan","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.jaut.2022.102887_bib160","doi-asserted-by":"crossref","first-page":"101r","DOI":"10.1126\/scitranslmed.aaf4964","article-title":"Noninvasive low-level laser therapy for thrombocytopenia","volume":"8","author":"Zhang","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jaut.2022.102887_bib161","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s40744-022-00469-2","article-title":"Plasma exchange in a patient with immune thrombocytopenia associated with antiphospholipid syndrome hospitalized for COVID-19","volume":"9","author":"Boggio","year":"2022","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.jaut.2022.102887_bib162","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.3324\/haematol.2020.261099","article-title":"Splenectomy for immune thrombocytopenia: the evolution and preservation of treatment","volume":"105","author":"Remiker","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jaut.2022.102887_bib163","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/blood-2017-09-742353","article-title":"Splenectomy for immune thrombocytopenia: down but not out","volume":"131","author":"Chaturvedi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2022.102887_bib164","first-page":"1","article-title":"Splenectomy has a limited role in the management of lupus with thrombocytopenia","volume":"29","author":"Alarcon-Segovia","year":"2002","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2022.102887_bib165","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s10067-018-3979-4","article-title":"Splenectomy in systemic lupus erythematosus and autoimmune hematologic disease: a comparative analysis","volume":"37","author":"Barron","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2022.102887_bib166","first-page":"286","article-title":"Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus, Ann","volume":"240","author":"You","year":"2004","journal-title":"Surgery"},{"key":"10.1016\/j.jaut.2022.102887_bib167","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s10067-013-2230-6","article-title":"Efficacy and safety of laparoscopic splenectomy in thrombocytopenia secondary to systemic lupus erythematosus","volume":"32","author":"Zhou","year":"2013","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2022.102887_bib168","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/rheumatology\/key072","article-title":"Thrombopoietin receptor agonist, splenectomy and intravenous immunoglobulin for immune thrombocytopaenia with systemic lupus erythematosus","volume":"57","author":"Sofue","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2022.102887_bib169","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2016-04-710285","article-title":"Corticosteroids compared with intravenous immunoglobulin for the treatment of immune thrombocytopenia in pregnancy","volume":"128","author":"Sun","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2022.102887_bib170","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/09537104.2019.1640870","article-title":"Managing ITP and thrombocytopenia in pregnancy","volume":"31","author":"Eslick","year":"2020","journal-title":"Platelets"},{"key":"10.1016\/j.jaut.2022.102887_bib171","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221095226","article-title":"Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study","volume":"13","author":"Zhu","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jaut.2022.102887_bib172","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1182\/blood.2020007594","article-title":"Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study","volume":"136","author":"Michel","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2022.102887_bib173","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100638","article-title":"Thrombocytopenia in pregnancy: diagnosis and approach to management","volume":"40","author":"Pishko","year":"2020","journal-title":"Blood Rev."},{"key":"10.1016\/j.jaut.2022.102887_bib174","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/bjh.15668","article-title":"Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients","volume":"184","author":"Palandri","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jaut.2022.102887_bib175","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00277-012-1567-2","article-title":"Immune thrombocytopenia in the elderly: clinical course in 525 patients from a single center in China","volume":"92","author":"Zhou","year":"2013","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.jaut.2022.102887_bib176","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/bjh.17935","article-title":"Primary immune thrombocytopenia in very elderly patients: particularities in presentation and management: results from the prospective CARMEN-France Registry","volume":"196","author":"Sokal","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jaut.2022.102887_bib177","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/bjh.17976","article-title":"Immune thrombocytopenia in the elderly: immunosenescent and clinical diversity","volume":"196","author":"Cunningham","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jaut.2022.102887_bib178","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/ejh.12839","article-title":"Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response","volume":"98","author":"Marangon","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.jaut.2022.102887_bib179","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/blood.2021010735","article-title":"Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia","volume":"138","author":"Palandri","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2022.102887_bib180","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejim.2018.09.005","article-title":"Management of immune thrombocytopenia in elderly patients","volume":"58","author":"Lucchini","year":"2018","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.jaut.2022.102887_bib181","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/ACO.0000000000000999","article-title":"Perioperative thrombocytopenia","volume":"34","author":"Lombard","year":"2021","journal-title":"Curr. Opin. Anaesthesiol."},{"key":"10.1016\/j.jaut.2022.102887_bib182","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/bjh.14423","article-title":"Guidelines for the use of platelet transfusions","volume":"176","author":"Estcourt","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jaut.2022.102887_bib183","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/blood-2014-10-605493","article-title":"Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality","volume":"125","author":"Goel","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2022.102887_bib184","doi-asserted-by":"crossref","first-page":"e640","DOI":"10.1016\/S2352-3026(20)30227-1","article-title":"Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial","volume":"7","author":"Arnold","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jaut.2022.102887_bib185","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/bjh.15280","article-title":"Romiplostim for the management of perioperative thrombocytopenia","volume":"182","author":"Al-Samkari","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jaut.2022.102887_bib186","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2141.1990.tb02569.x","article-title":"Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases","volume":"74","author":"Quiquandon","year":"1990","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jaut.2022.102887_bib187","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1055\/s-0039-1684032","article-title":"Immunomodulatory Second-Line therapies for immune thrombocytopenia","volume":"39","author":"Lambert","year":"2019","journal-title":"H\u00e4mostaseologie"},{"key":"10.1016\/j.jaut.2022.102887_bib188","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1046\/j.1365-2141.2001.02893.x","article-title":"Cyclosporin a for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy","volume":"114","author":"Kappers-Klunne","year":"2001","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jaut.2022.102887_bib189","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1177\/0961203317711011","article-title":"Efficacy and safety of tacrolimus in systemic lupus erythematosus patients with refractory thrombocytopenia: a retrospective study","volume":"27","author":"Li","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2022.102887_bib190","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1745-7254.2005.00088.x","article-title":"Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura","volume":"26","author":"Zhang","year":"2005","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jaut.2022.102887_bib191","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/ejh.12586","article-title":"Vincristine efficacy and safety in treating immune thrombocytopenia: a retrospective study of 35 patients","volume":"96","author":"Stirnemann","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.jaut.2022.102887_bib192","doi-asserted-by":"crossref","first-page":"E175","DOI":"10.1002\/ajh.25119","article-title":"Sirolimus as a rescue therapy in children with immune thrombocytopenia refractory to mycophenolate mofetil","volume":"93","author":"Miano","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jaut.2022.102887_bib193","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ajh.24999","article-title":"Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: a multicenter retrospective cohort study of 71 adults","volume":"93","author":"Serris","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jaut.2022.102887_bib194","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.23518","article-title":"Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia","volume":"88","author":"Mahevas","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jaut.2022.102887_bib195","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/ajh.23272","article-title":"Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia","volume":"87","author":"Zaja","year":"2012","journal-title":"Am. J. Hematol."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841122000956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841122000956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:37:45Z","timestamp":1760258265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841122000956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":195,"alternative-id":["S0896841122000956"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2022.102887","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic lupus erythematosus-complicating immune thrombocytopenia: From pathogenesis to treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2022.102887","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102887"}}